Plant-Derived Polysaccharides as Modulators of the Gut–Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Meartinos Reamos
Department of Computer Science and Engineering, University at Buffalo, Buffalo, NY, USA.
martinsramos@buffalo.edu

Henrik R. Baker
Department of Computer Science, University of Central Florida, Orlando, FL, USA.
henrikbaker03@ucf.edu

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a global health challenge, driven by intertwined dietary, microbial, and host metabolic perturbations. The gut–liver axis constitutes a bidirectional communication system whose architecture integrates intestinal barrier integrity, microbial ecology, bile acid signaling, and immune surveillance. Within this complex adaptive system, plant-derived polysaccharides exhibit a striking capacity to orchestrate multi-level modulatory effects that extend far beyond their traditional classification as dietary fibers. This paper presents a systems-level analysis of how structurally diverse polysaccharides interface with the gut–liver axis, emphasizing architectural trade-offs, network robustness, governance of physiological boundaries, and deployment considerations. Rather than cataloging molecular interactions in isolation, we characterize the gut–liver axis as a layered infrastructure with modular functional units, feedback regulation, and emergent properties that determine resilience against steatotic insults. Plant polysaccharides are positioned as soft modulators that engage multiple nodes simultaneously, enabling context-dependent reconfiguration of microbial consortia, reinforcement of epithelial barrier architecture, and tuning of hepatic inflammatory and metabolic circuits. The discussion extends to structural trade-offs among polysaccharide complexity, fermentability, and site-specific activity, highlighting how source-dependent molecular topologies influence system-level outcomes. Further, we examine the infrastructure required for scalable production, standardization, and equitable deployment of polysaccharide-based interventions, addressing sustainability of raw material supply chains and regulatory governance challenges that straddle the boundaries between food, supplement, and therapeutic agent. By reframing polysaccharide action through the lens of systems architecture and policy, this analysis reveals the deep coupling between molecular design, ecological resilience, and societal implementation that must be navigated to translate gut–liver axis modulation into population-wide metabolic health benefits.

Keywords

gut–liver axis, metabolic dysfunction-associated steatotic liver disease, plant polysaccharides, systems architecture, microbiota, resilience, infrastructure governance.

1. Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly designated non-alcoholic fatty liver disease, represents a spectrum of hepatic pathologies extending from simple steatosis through steatohepatitis to fibrosis and cirrhosis. Its prevalence has risen in parallel with the global obesity pandemic, yet its pathophysiological substrate extends far beyond hepatocyte lipid accumulation. Contemporary systems-oriented models recognize MASLD as an emergent property of multi-organ network failure, wherein intestinal, microbial, immune, and hepatic subsystems interact through a dense web of molecular communication channels collectively termed the gut–liver axis. This axis is not a simple linear conduit but a highly reticulated infrastructure characterized by nested feedback loops, functional redundancy, and critical interdependence among barrier, metabolic, and immunological modules. Disruption of any single node can propagate through the network, producing non-linear deterioration that frustrates reductionist therapeutic targeting. In this context, plant-derived polysaccharides have attracted growing attention not merely as passive bulking agents or prebiotic substrates, but as multivalent modulatory molecules capable of engaging multiple gut–liver axis components in a coordinated fashion.

The conventional biomedical narrative addresses polysaccharides primarily through the lens of short-chain fatty acid (SCFA) production following colonic fermentation. While SCFAs undoubtedly represent one important effector pathway, this view neglects the broader information-bearing capabilities of polysaccharides, their direct interactions with intestinal epithelial receptors, their capacity to restructure the physical architecture of the mucus barrier, and their influence on bile acid enterohepatic circulation. A systems paradigm requires us to treat each plant polysaccharide as a structurally encoded message that the gut–liver axis decodes through distributed sensing mechanisms, yielding pleiotropic outcomes that depend on the initial state of the system, its ecological composition, and the temporal dynamics of exposure. From an architectural standpoint, the gut–liver axis possesses the hallmarks of a layered defense-in-depth infrastructure: a mucus-biofilm boundary layer, a cellular junction-gated epithelial firewall, a portal venous information highway, and a hepatic decision-making center that integrates metabolic and immune signals. The insertion of exogenous polysaccharides into this architecture generates ripple effects that may either restore resilient homeostasis or expose hidden vulnerabilities depending on dosage, molecular structure, and host context. The present analysis applies this architectural lens to re-examine the evidence linking plant-derived polysaccharides to MASLD modulation, foregrounding system-level trade-offs that are often obscured in reductionist biochemical accounts. We further extend the discussion into largely uncharted territory: the infrastructure, sustainability, governance, and equity dimensions that will determine whether polysaccharide-based strategies can transition from benchtop promise to real-world metabolic health solutions.

2. The Gut–Liver Axis as a Layered Infrastructure

To appreciate how plant polysaccharides exert systemic effects, one must first understand the structural organization of the gut–liver axis as a multi-tiered communication infrastructure. The luminal compartment forms the outermost user-facing layer, where dietary components, microbial communities, and host secretions interact under dynamic physicochemical gradients. This layer interfaces with the mucosal barrier, a composite structure comprising the outer loose mucus stratum colonized by specific bacterial phylotypes and the inner dense stratum that maintains sterility in the healthy state. The epithelial monolayer constitutes the next architectural tier, functioning as a regulated gateway whose permeability is controlled by tight junction protein complexes that are themselves subject to modulation by microbial

metabolites, cytokines, and dietary factors. Beneath the epithelium, the lamina propria houses a dense network of immune cells, including dendritic cells that sample luminal content and transmit antigenic and metabolic signals to mesenteric lymph nodes, forming a distributed immunological sensing infrastructure. The portal vein then concentrates all venous outflow from the intestines and delivers it directly to the hepatic sinusoids, ensuring that the liver is the first systemic organ to encounter gut-derived nutrients, microbial products, and signaling molecules. Within the liver, sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, and hepatocytes are spatially organized into microarchitectural units that facilitate efficient extraction and processing of portal signals. This spatial arrangement means that the liver effectively operates as a central information integration node for the entire gut-originating data stream.

The infrastructure metaphor proves useful because it highlights several properties relevant to MASLD and polysaccharide intervention. First, the axis exhibits modularity: disruptions can remain compartmentalized within a single layer, such as a mucus thinning defect, for a prolonged period before cascading across interfaces. Second, it incorporates layered redundancy; for example, both intestinal alkaline phosphatase and antimicrobial peptides contribute to luminal bacterial containment, and only dual failure exposes the epithelium to excessive pathogen-associated molecular patterns (PAMPs). Third, the system relies on bidirectional feedback: hepatic bile acid synthesis shapes the intestinal microbial ecosystem, which in turn biotransforms primary bile acids into secondary species that signal through farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) to regulate hepatic metabolism and inflammation [1,2]. In MASLD, this feedback architecture becomes destabilized, typically through a combination of increased intestinal permeability, alteration in bile acid pool composition, and systemic low-grade inflammation that further exacerbates barrier dysfunction. The gut–liver axis thus represents a fragile equilibrium sensitive to both acute insults and sustained low-grade perturbations such as chronic high-fat, high-sugar dietary patterns. Within this framework, plant polysaccharides can be conceptualized as infrastructural inputs that introduce multiple simultaneous modulatory signals into different layers, potentially restoring alignment among otherwise discordant subsystems.

3. Structural Architecture of Plant-Derived Polysaccharides

Before examining mechanisms, it is essential to appreciate that plant-derived polysaccharides are not a homogeneous substance class but a vast ensemble of macromolecules whose biological activities are dictated by their structural architecture. Polysaccharides are biopolymers composed of monosaccharide units linked by glycosidic bonds in linear or branched configurations. Their three-dimensional conformations, molecular weight distributions, charge densities, and patterns of substituent groups such as acetyl or sulfate moieties collectively determine their solubility, resistance to digestive enzymes, fermentability by gut bacteria, and affinity for host cell receptors. Common structural categories include beta-glucans from cereals and fungi, pectic polysaccharides rich in galacturonic acid from fruit and vegetable cell walls, heteroxylans from cereal brans, inulin-type fructans from chicory and agave, glucomannans from konjac, and sulfated galactans from red seaweeds. Each architectural class presents a distinct information surface to the gut ecosystem.

From a systems perspective, the structural complexity of polysaccharides can be viewed as a form of molecular barcoding that enables differential recognition by specific bacterial taxa and host receptors. For example, the degree of methylation and acetylation in pectins

modulates their susceptibility to bacterial polysaccharide lyases and carbohydrate esterases, thereby shaping which microbial guilds can access them as substrates [3,4]. High molecular weight and extensive branching generally slow fermentation and extend the polysaccharide's physical presence along the colonic length, whereas linear, low molecular weight chains undergo rapid proximal fermentation. This introduces a critical architectural trade-off: rapid fermentability maximizes SCFA yield in the proximal colon but may leave the distal colon starved of substrate, while slowly fermentable polysaccharides provide more sustained microbial support along the entire colon but generate lower peak SCFA concentrations. The spatial gradient of fermentation is not merely a quantitative variable; it determines which epithelial segments receive SCFA signals and how the microbial community partitions along the intestinal longitudinal axis, with consequences for regional barrier function and immune signaling.

Additionally, certain polysaccharides possess gelling, viscosifying, or emulsifying properties that alter the physical architecture of the intestinal lumen. High-viscosity polysaccharides such as beta-glucan and glucomannan retard gastric emptying and slow glucose absorption in the small intestine, thereby dampening postprandial glycemic and insulinemic excursions that are upstream drivers of hepatic de novo lipogenesis [5]. These same rheological properties influence bile acid sequestration and reabsorption, shifting the enterohepatic circulation in ways that can upregulate hepatic bile acid synthesis and promote a more anti-steatotic bile acid profile. At the microscopic scale, polysaccharides can bind directly to bile acids through hydrophobic and ionic interactions, reducing their micellar availability for lipid absorption and altering the composition of the bile acid pool returning to the liver. The structural diversity of polysaccharides therefore encodes functional capabilities that extend across multiple physical scales, from molecular recognition events at receptor interfaces to macroscopic rheological modification of gut content flow.

4. Modulatory Mechanisms at the Gut–Liver Interface

The systemic effects of plant polysaccharides on MASLD arise from concurrent action at multiple nodes of the gut–liver network. At the most proximal level, many polysaccharides serve as substrates for specific bacterial consortia, selectively enriching taxa that produce metabolites beneficial for hepatic health. Short-chain fatty acids, particularly acetate, propionate, and butyrate, are the most extensively characterized products of this fermentation process. Butyrate serves a dual role, acting both as the primary energy source for colonocytes and as a histone deacetylase inhibitor that reinforces tight junction protein expression and suppresses inflammatory signaling in the intestinal epithelium [6,7]. By strengthening the epithelial barrier, butyrate reduces the translocation of lipopolysaccharide (LPS) and other PAMPs into the portal circulation, thereby attenuating the tonic stimulation of hepatic toll-like receptor 4 (TLR4) signaling that drives Kupffer cell activation and inflammatory cytokine production in MASLD [8]. Propionate and acetate, delivered to the liver via the portal vein, exert complementary metabolic effects: propionate serves as a gluconeogenic substrate and may modulate hepatic lipid metabolism through AMP-activated protein kinase (AMPK) activation, while acetate can be utilized for lipogenesis or oxidized depending on the prevailing metabolic context. The net hepatic outcome is therefore not determined by any single fatty acid but by the collective ratio and temporal delivery pattern of SCFAs, which are themselves shaped by the fermentative architecture of the polysaccharide source.

Beyond SCFA production, polysaccharides influence bile acid metabolism through multiple interconnected pathways. By altering the composition of the gut microbiota, polysaccharides

shift the profile of bacterial bile salt hydrolase activity and the capacity for 7-alpha-dehydroxylation, thereby modifying the relative abundance of primary and secondary bile acids [9]. Given that secondary bile acids such as deoxycholic acid and lithocholic acid differentially activate FXR and TGR5 compared to primary species, the polysaccharide-induced microbiome restructuring has profound implications for hepatic metabolic regulation. FXR activation in the liver suppresses bile acid synthesis via small heterodimer partner (SHP) induction and simultaneously inhibits lipogenesis by modulating peroxisome proliferator-activated receptor alpha (PPAR-alpha) and sterol regulatory element-binding protein 1c (SREBP-1c) pathways. TGR5 activation in intestinal L-cells promotes glucagon-like peptide 1 (GLP-1) secretion, which enhances insulin sensitivity and may indirectly reduce hepatic steatosis [10]. The system-level consequence is that polysaccharides acting at the gut microbial level can reconfigure the entire bile acid-FXR-FGF15/19 enterohepatic signaling axis, generating anti-steatotic outcomes that are not achievable through direct hepatic pharmacotherapy alone.

Furthermore, specific polysaccharide structures engage host immune receptors directly, independent of fermentation. Beta-glucans, for instance, are recognized by dectin-1 and complement receptor 3 on dendritic cells and macrophages in the intestinal lamina propria, triggering immunomodulatory cascades that can reduce hepatic inflammation [11]. Some pectic polysaccharides interact with galectin-3, a protein implicated in fibrogenesis and metabolic inflammation, offering a potential mechanism for direct attenuation of hepatic stellate cell activation. The concept that polysaccharides function simultaneously as prebiotic substrates and as direct signaling ligands adds a layer of redundancy and robustness to their action: even if microbial fermentation is partially compromised, for example, by antibiotic use or disease-associated dysbiosis, the direct receptor-mediated effects can still partially preserve barrier enhancement and immune modulation. This architectural redundancy mirrors the defense-in-depth principle observed in engineered resilient systems, where multiple independent protective layers ensure continued function despite partial subsystem failure.

5. System-Level Dynamics and Network Robustness

Treating the gut–liver axis as a complex adaptive system invites an examination of how polysaccharide interventions influence dynamic stability, attractor states, and functional resilience. In a healthy system, the gut microbial ecosystem exhibits high alpha-diversity and functional redundancy that confer resilience against dietary and environmental perturbations. MASLD is associated with a loss of this diversity and a shift toward an alternative stable state characterized by an increased Firmicutes-to-Bacteroidetes ratio, decreased abundance of butyrate-producing Clostridiales, and expansion of potentially pathogenic Proteobacteria [12]. This dysbiotic state tends to be self-reinforcing because altered bile acid profiles and increased gut permeability create selective conditions that further disadvantage health-associated taxa. In systems terms, the ecosystem has transitioned into a pathological attractor basin from which spontaneous recovery is thermodynamically unlikely without external perturbation.

Plant polysaccharides can be interpreted as a carefully designed perturbation signal intended to nudge the gut ecosystem back toward a healthy attractor. The efficacy of such an intervention depends not only on the magnitude of the perturbation but also on its ability to reshape the ecological landscape so that the desired state becomes a stable equilibrium rather than a transient excursion. Some polysaccharides appear capable of facilitating this attractor switch through cross-feeding networks. For example, primary fermenters such as

Bifidobacterium and Lactobacillus that metabolize inulin-type fructans release partially degraded oligosaccharides, lactate, and acetate that serve as substrates for secondary fermenters like Anaerobutyricum hallii and Faecalibacterium prausnitzii, which in turn produce butyrate [13]. This metabolic handoff creates a positive feedback loop wherein butyrate production helps lower luminal pH, further favoring beneficial taxa and inhibiting pathogens. The restoration of a butyrate-rich, mildly acidic colonic environment can subsequently enhance epithelial barrier function and reduce inflammatory signaling, decreasing the selection pressure that originally favored dysbiotic taxa. This process illustrates a key principle of robust system design: interventions that harness endogenous network interactions and positive feedback loops can achieve durable state transitions with lower exogenous energy input than interventions that attempt to override system dynamics with a single strong signal.

However, the very complexity that enables such emergent resilience also introduces vulnerability to unintended consequences. Polysaccharides with narrow substrate specificity that strongly enrich a limited set of taxa risk creating a fragile community overly dependent on that specific fiber type, leading to collapse if the fiber source is withdrawn. Broad-spectrum fermentable polysaccharides may benefit a wider range of taxa but risk excessive gas production and bloating, limiting tolerability in some populations. There exists, therefore, a structural trade-off between specificity and tolerability that mirrors classic engineering decisions in network design: highly precise interventions risk brittleness, while broad interventions risk side effects. The temporal dynamics of polysaccharide administration further complicate this picture. Intermittent dosing schedules may create oscillatory conditions that prevent any single microbial assemblage from becoming dominant, potentially preserving functional flexibility, while continuous administration may drive deterministic ecological shifts that, if beneficial, produce stable improvement but carry the risk of eventual resistance or adaptation by opportunistic pathogens. These dynamic considerations remain underexplored in the current MASLD literature but are essential for designing robust polysaccharide-based interventions that can withstand the complexity of real-world application.

6. Infrastructure for Production, Standardization, and Deployment

Translating the scientific rationale for polysaccharide-mediated gut–liver axis modulation into scalable interventions confronts a formidable infrastructure challenge that spans agricultural production, extraction technology, quality assurance, and formulation science. Unlike synthetic small-molecule drugs that can be manufactured to precise purity specifications through well-characterized chemical pathways, plant-derived polysaccharides are inherently heterogeneous products whose molecular weight distribution, branching architecture, and substituent pattern vary with cultivar, growing conditions, harvest timing, and post-harvest processing [14]. This biological variability presents a fundamental tension between the chemical complexity that likely underlies polysaccharide bioactivity and the industrial demand for standardized, reproducible products suitable for clinical evidence generation and regulatory approval. Current infrastructure for polysaccharide production relies largely on conventional extraction methods using hot water, alkaline, or enzymatic treatments, followed by precipitation and drying. These processes, while scalable, often result in partial degradation of heat-labile structures, co-extraction of polyphenolic or proteinaceous impurities, and batch-to-batch variation that can confound biological readouts. Emerging technologies such as ultrasound-assisted extraction, microwave-assisted extraction, and

membrane-based fractionation offer more precise control over molecular weight cutoffs and can preserve labile substituents, but their capital and energy costs remain substantial barriers to widespread deployment in lower-resource settings.

Standardization represents another critical infrastructural bottleneck. Pharmacopoeial monographs for many polysaccharide-rich gums and mucilages exist, but they typically specify bulk physicochemical parameters such as viscosity, loss on drying, and ash content that are insufficient to guarantee biological equivalence. Given that even minor structural differences in acetylation pattern or branching density can affect microbial fermentation kinetics and receptor affinity, more sophisticated analytical approaches including size-exclusion chromatography with multi-angle light scattering, monosaccharide compositional analysis, and linkage analysis by methylation-GC-MS are required to establish meaningful quality benchmarks [15]. These methods demand expensive instrumentation and specialized expertise, creating a divergence between the capabilities of well-funded centralized laboratories and the realities of decentralized production in agricultural regions. The governance challenge, then, is to design regulatory frameworks that enforce sufficient standardization to protect consumers and enable reproducible clinical evidence, without imposing technical barriers so stringent that they exclude traditional or community-scale producers from the market. This tension is particularly acute in the context of polysaccharides derived from plants with long histories of traditional medicinal use, where cultural knowledge and biodiversity stewardship intersect with global intellectual property regimes.

7. Governance, Fairness, and Policy Implications

The prospect of deploying plant polysaccharides as population-level modulators of the gut–liver axis in MASLD raises profound governance and fairness questions that extend well beyond the traditional boundaries of biomedical regulation. Classification of polysaccharide products along the food-supplement-drug continuum represents a persistent policy ambiguity with direct consequences for market access, evidentiary requirements, and reimbursement. A polysaccharide product positioned as a conventional food or dietary supplement can reach consumers with comparatively low regulatory hurdles but cannot legally carry disease-prevention or treatment claims, limiting incentives for rigorous clinical trials and creating an evidence vacuum exploited by low-quality formulations. Conversely, purification and standardization of a specific polysaccharide fraction to support a drug claim requires the extensive investment associated with pharmaceutical development, raising the price point in a way that may exclude the populations at highest risk for MASLD, including lower-income communities that experience disproportionate burdens of metabolic disease driven by food environment inequities [16]. This tension is not unique to polysaccharides but is particularly acute for interventions derived from common food sources, where patentability and exclusivity concerns collide with the notion that such compounds belong to a shared nutritional commons.

A systems-oriented governance model would require a more nuanced regulatory architecture that acknowledges the intermediate nature of polysaccharide-based interventions. One approach under discussion in some jurisdictions involves the creation of a distinct regulatory category for "nutraceutical therapeutics" that demands proportionate evidence of safety and efficacy based on intended use and risk, without forcing products into either the unregulated food environment or the full pharmaceutical pathway. Such a framework could incorporate tiered evidentiary standards, where substantiation of structure-function effects on gut barrier integrity or microbial diversity through well-designed human studies might support moderate

health claims, while disease-modification claims would require randomized controlled trials with histologic endpoints. However, designing and implementing such a tiered system internationally faces formidable coordination problems given the heterogeneity of regulatory traditions and the globalized nature of supply chains for many polysaccharide-rich plant materials. Furthermore, the protection of genetic resources and associated traditional knowledge under the Nagoya Protocol introduces obligations that many polysaccharide producers and researchers are ill-equipped to navigate, creating risks of both biopiracy allegations and underutilization of valuable botanical diversity due to legal uncertainty [17].

Fairness concerns also arise at the implementation level. Even if effective, safe, and regulatory-approved polysaccharide products become available, their distribution through existing healthcare and retail infrastructures may reproduce or amplify existing disparities. In many high-income countries, dietary supplements are paid out-of-pocket, and premium functional foods carrying specific gut-health claims are priced beyond the reach of low-income households who bear the highest MASLD burden. Public health policies that rely on individual dietary supplementation rather than structural interventions to improve the food environment risk shifting responsibility onto consumers while leaving systemic drivers of metabolic disease unaddressed. A more equitable deployment strategy would integrate polysaccharide-based interventions into broader food system reforms, potentially through fortification of staple foods or through agricultural policies that incentivize cultivation of polysaccharide-rich traditional crops and their incorporation into public nutrition programs. Such an approach demands intersectoral governance mechanisms that bridge health, agriculture, trade, and environmental policymaking domains, a coordination challenge that few nations have successfully addressed.

8. Sustainability and Supply Chain Robustness

The source plants for the most studied bioactive polysaccharides span multiple continents and ecological zones, including konjac from East Asia, agave from arid regions of the Americas, guar from the Indian subcontinent, chicory from temperate Europe, and assorted seaweeds harvested from both wild and cultivated marine systems. The projected expansion in demand for polysaccharide-based health products, if trends toward personalized nutrition and gut health awareness continue, will exert significant pressure on these raw material supply chains, raising sustainability concerns that cannot be divorced from clinical efficacy discussions. Seaweed-derived sulfated polysaccharides such as fucoidan and carrageenan illustrate the dual-edged nature of this expansion. While mariculture of seaweed requires no freshwater, arable land, or fertilizer, and can contribute to coastal ecosystem services including nutrient uptake and habitat provision, unregulated expansion risks genetic pollution of wild populations, introduction of invasive genotypes, and localized depletion of dissolved nutrients that affect primary productivity beyond the farm boundaries. Life-cycle assessment methodologies applied to terrestrial polysaccharide crops such as chicory indicate that inulin-type fructan production carries a comparatively low carbon and water footprint relative to many animal-sourced functional ingredients, yet monoculture expansion can contribute to soil degradation and biodiversity loss if not managed through regenerative agricultural practices.

Supply chain robustness for polysaccharide products also intersects with climate change vulnerability. Many polysaccharide source plants are cultivated in regions projected to experience increased drought frequency, heat stress, or extreme precipitation events under near-term climate scenarios. Guar, for example, has historically experienced dramatic price volatility driven by monsoon variability in Rajasthan and by fluctuations in hydraulic

fracturing industry demand, which competes for guar gum as a thickening agent. Developing geographically diversified sourcing portfolios and investing in breeding programs for climate-resilient cultivars represent system-level adaptation strategies that will increasingly determine the reliability of the polysaccharide supply base. From a systems design perspective, the polysaccharide production infrastructure exhibits characteristics of a complex supply network with multiple bottlenecks; extraction and processing capacity is often concentrated in a small number of facilities, creating vulnerabilities that raw material abundance alone cannot mitigate. Building decentralized, modular processing infrastructure that can operate closer to cultivation sites, potentially using renewable energy inputs and low-water extraction technologies, could enhance both environmental sustainability and supply continuity.

Another underexamined sustainability dimension concerns the competition between polysaccharide extraction for human health applications and the use of the same feedstocks for animal feed, biofuel production, or other industrial purposes. Chicory roots, for instance, are grown for inulin extraction for both human food and industrial applications, and diversion of agricultural land toward pharmaceutical-grade polysaccharide production could have ripple effects on regional food crop availability. Sustainability governance thus demands a holistic approach that evaluates polysaccharide value chains not in isolation but as components of interconnected food-energy-water systems. Certification schemes that incorporate biodiversity, soil health, water stewardship, and fair labor criteria into the sourcing of polysaccharide ingredients are beginning to emerge, though their adoption remains voluntary and fragmented.

9. Forward-Looking Perspectives and Integration

Integrating the diverse threads of molecular architecture, gut–liver network dynamics, infrastructural scaling, regulatory governance, and sustainability reveals that plant-derived polysaccharides cannot be reduced to simple bioactive agents operating through linear pathways. They represent a system intervention whose net effect emerges from the interplay between structural specificity encoded in glycosidic bond sequences and the contextual variables of host microbiota, dietary background, and disease stage. Future research must adopt experimental designs that embrace this complexity rather than attempting to eliminate it. Cross-over trials that systematically vary polysaccharide structure parameters such as molecular weight, branching degree, and charge density while measuring multi-omics readouts across stool, plasma, and liver biopsies would permit the parsing of structure-activity relationships at a systems level. The development of organ-on-chip platforms that co-culture intestinal epithelial cells with defined microbial consortia and hepatic organoids under controlled perfusion conditions might offer a reductionist complement that isolates specific architectural interactions without sacrificing the multi-compartment topology of the gut–liver axis [18]. Computational models, particularly agent-based models that simulate microbial metabolic networks and genome-scale metabolic reconstructions of hepatocyte metabolism coupled through a virtual portal circulation, could function as integrative frameworks for predicting the system-level response to polysaccharide perturbations and for identifying optimal structural characteristics for a given host phenotype [19].

The governance, equity, and sustainability dimensions discussed here demand that biomedical researchers engage with disciplines and stakeholders far outside their conventional purview, including agricultural economists, trade policy specialists, traditional knowledge holders, and community health advocates. If polysaccharide science is to fulfill its potential as a scalable strategy for MASLD mitigation, the conversation must expand beyond chemical characterization and randomized trials to encompass the full sociotechnical system through

which these molecules will be produced, regulated, distributed, and consumed. Co-design of research agendas with populations disproportionately affected by MASLD could help ensure that the resulting products align with culturally acceptable dietary patterns and economic realities. Furthermore, new forms of public-private partnership that diverge from the standard pharmaceutical exclusivity model may be required to generate the clinical evidence base needed for regulatory approval of non-patentable polysaccharide compositions, perhaps funded through consortia involving government health agencies, philanthropic organizations, and industry stakeholders willing to share the resulting data as a public good [20].

10. Conclusion

This analysis has reframed plant-derived polysaccharides as modulators of the gut–liver axis in MASLD through an explicitly system-oriented lens. The gut–liver axis is a layered, bidirectional infrastructure exhibiting modularity, redundancy, and feedback regulation that jointly determine its vulnerability to steatotic disease and its responsiveness to dietary interventions. Plant polysaccharides, by virtue of their immense structural diversity, act simultaneously at multiple levels of this infrastructure: restructuring the mucus barrier interface, serving as selective substrates for butyrogenic microbial consortia, physically modifying luminal rheology and bile acid enterohepatic flux, and directly engaging host immune receptors in the lamina propria. The net effect on hepatic steatosis, inflammation, and fibrosis is an emergent property of this multi-nodal perturbation, dependent on both the molecular architecture of the polysaccharide and the initial configuration of the host system. We have highlighted fundamental trade-offs between fermentability and persistency, between specificity and tolerability, and between structural complexity and manufacturability that must be navigated in the design of robust polysaccharide interventions. Extending the analysis beyond molecular mechanisms, we have mapped the infrastructural, regulatory, fairness, and sustainability challenges that will constrain or enable real-world deployment. The polysaccharide value chain, from agricultural production through extraction and standardization to clinical integration, presents multiple bottlenecks and inequities that demand interdisciplinary governance innovations. Ultimately, the modulation of the gut–liver axis through plant polysaccharides is not merely a biochemical problem but a systems design challenge that intertwines molecular ecology with agricultural policy, global trade, regulatory science, and public health strategy. Addressing MASLD through this lens offers a paradigm for the broader integration of systems thinking into the development of nutrition-based interventions for complex chronic diseases.

References

1. Sonoda, J., Pei, L., & Evans, R. M. (2008). Nuclear receptors: Decoding metabolic disease. FEBS Letters, 582(1), 2–9.

2. Wahlström, A., Sayin, S. I., Marschall, H. U., & Bäckhed, F. (2016). Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metabolism, 24(1), 41–50.

3. Larsen, N., Bussolo de Souza, C., Krych, L., Cahu, T. B., Wiese, M., Kot, W., Hansen, K. M., Blennow, A., Venema, K., & Jespersen, L. (2019). Potential of pectins to beneficially modulate the gut microbiota depends on their structural properties. Frontiers in Microbiology, 10, 223.

4. Ndeh, D., & Gilbert, H. J. (2018). Biochemistry of complex glycan depolymerisation by the human gut microbiota. FEMS Microbiology Reviews, 42(2), 146–164.

5. El Khoury, D., Cuda, C., Luhovyy, B. L., & Anderson, G. H. (2012). Beta glucan: Health benefits in obesity and metabolic syndrome. Journal of Nutrition and Metabolism, 2012, 851362.

6. Hamer, H. M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F. J., & Brummer, R. J. (2008). Review article: The role of butyrate on colonic function. Alimentary Pharmacology & Therapeutics, 27(2), 104–119.

7. Peng, L., Li, Z. R., Green, R. S., Holzman, I. R., & Lin, J. (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. Journal of Nutrition, 139(9), 1619–1625.

8. Miura, K., & Ohnishi, H. (2014). Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 20(23), 7381–7391.

9. Ridlon, J. M., Kang, D. J., & Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. Journal of Lipid Research, 47(2), 241–259.

10. Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., Pellicciari, R., Auwerx, J., & Schoonjans, K. (2009). TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism, 10(3), 167–177.

11. Brown, G. D., & Gordon, S. (2003). Fungal beta-glucans and mammalian immunity. Immunity, 19(3), 311–315.

12. Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020). Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders. Nature Reviews Gastroenterology & Hepatology, 17(5), 279–297.

13. Rivière, A., Selak, M., Lantin, D., Leroy, F., & De Vuyst, L. (2016). Bifidobacteria and butyrate-producing colon bacteria: Importance and strategies for their stimulation in the human gut. Frontiers in Microbiology, 7, 979.

14. Cui, S. W., & Wang, Q. (2009). Cell wall polysaccharides in cereals: Chemical structures and functional properties. Structural Chemistry, 20(2), 291–297.

15. Pettolino, F. A., Walsh, C., Fincher, G. B., & Bacic, A. (2012). Determining the polysaccharide composition of plant cell walls. Nature Protocols, 7(9), 1590–1607.

16. Zhao K, et al. Phyllostachys nigra (Lodd ex Lindl) derived polysaccharide with enhanced glycolipid metabolism regulation and mice gut microbiome. Int J Biol Macromol. 2024;257:128588.

17. Buck, M., & Hamilton, C. (2011). The Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the Convention on Biological Diversity. Review of European Community & International Environmental Law, 20(1), 47–61.

18. Jalili-Firoozinezhad, S., Gazzaniga, F. S., Calamari, E. L., Camacho, D. M., Fadel, C. W., Bein, A., Swenor, B., Nestor, B., Cronce, M. J., Tovaglieri, A., Levy, O., Gregory, K. E., Breault, D. T., Cabral, J. M. S., Kasper, D. L., Novak, R., & Ingber, D. E. (2019). A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nature Biomedical Engineering, 3(7), 520–531.

19. Thiele, I., Sahoo, S., Heinken, A., Hertel, J., Heirendt, L., Aurich, M. K., & Fleming, R. M. (2020). Personalized whole-body models integrate metabolism, physiology, and the gut microbiome. Molecular Systems Biology, 16(5), e8982.

20. Hess, S., Laimer, M., & Wascher, D. (2019). Policy options for sustainable food environments: A conceptual framework for public and private governance. Food Policy, 82, 63–74.